Introduction
Genetic and genomic variability is intimately linked to differential disease risk among individuals. Gene expression can be modified by various genetic variants ranging from large structural variants (such as CNVs) to single nucleotide polymorphisms (SNPs). It is estimated that SNPs and CNVs capture 84% and 18%, respectively, of the total detected genetic variation in gene expression (Stranger et al., 2007) . Such genetic variants affecting gene expression are referred to as expression quantitative trait loci (eQTL). eQTL can affect transcription either in trans (by affecting expression at distally located genomic loci, including ones in different chromosomes) or in cis (by affecting expression of genomic loci at their immediate vicinity). While the mechanism by which cis-acting variants affect gene expression is well established, how exactly variants acting in trans modulate gene expression and contribute to disease susceptibility remains under investigation (Cookson et al., 2009) . microRNAs (miRNAs) (Bartel, 2004) bind to their target mRNAs (Lewis et al., 2003) and play a fundamental role in regulating gene expression primarily through post-transcriptional gene silencing via mRNA degradation or translational repression. As such, miRNAs could play an important role in mediating trans-acting effects on gene expression. In that respect, the potential of miRNAs to regulate expression of multiple genes could be an important component of the genetic architecture of complex disorders and traits. We have previously shown that 22q11.2 microdeletions, rare but recurrent de novo CNVs that predispose to cognitive dysfunction and schizophrenia mediate their effects at least in part due to pervasive miRNA-dependent effects on gene expression (Ambros et al., 2003; Stark et al., 2008; Xu et al., 2013) . This finding established that miRNAmediated trans effects on gene expression as an integral part of the pathogenesis of psychiatric and cognitive disorders (Xu et al., 2012) . However, whether the contribution of miRNAs to the genetic etiology of complex disorders extends beyond rare structural mutations to common risk variants remain unknown. Addressing this issue is a key step towards obtaining a comprehensive view of the role that miRNAs play on mediating the trans regulatory effects of various rare and common diseasepredisposing genetic variants.
To investigate whether miRNAs contribute to the trans regulatory effects of common genetic variants, we took advantage of a common SNP at codon 66 in the pro-domain of the Brain-Derived Neurotrophic Factor (BDNF) gene, which results in substitution of a valine by a methionine (Val66Met), leading to disrupted transportation of both the mRNA and protein to neuronal terminals and reduced activitydependent release of BDNF protein both in vitro and in vivo (Chen et al., 2004; Chiaruttini et al., 2009; Egan et al., 2003) . Val66Met SNP is a human-specific common genetic variant (Tettamanti et al., 2010) . The allelic frequency of BDNF Met is~20-30% in populations of European
